Blood Res.  2014 Jun;49(2):77-79. 10.5045/br.2014.49.2.77.

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism

• Yhim HY
• Bang SM

• KMID: 2172799
• DOI: http://doi.org/10.5045/br.2014.49.2.77

Abstract

No abstract available.

MeSH Terms

Anticoagulants*
Venous Thromboembolism*
Anticoagulants

Reference

1. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100:3484–3488. PMID: 12393647.

2. Wharin C, Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev. 2014; 28:1–8. PMID: 24360911.

3. Siegal DM, Garcia D. Anticoagulants in cancer. J Thromb Haemost. 2012; 10:2230–2241. PMID: 22943367.

4. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349:146–153. PMID: 12853587.

5. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342–2352. PMID: 19966341.

6. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129:764–772. PMID: 24344086.

7. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499–2510. PMID: 21128814.

8. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366:1287–1297. PMID: 22449293.

9. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369:799–808. PMID: 23808982.

10. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369:1406–1415. PMID: 23991658.

11. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11:21. PMID: 24053656.

12. Raskob GE, Buller H, Angchaisuksiri P, et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood. 2013; 122:abst 211. ASH Annual Meeting.

13. Schulman S, Eriksson H, Goldhaber SZ, et al. Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: A pooled analysis from re-cover and re-cover II. Blood. 2013; 122:abst 582. ASH Annual Meeting.